ChromaDex (NASDAQ:CDXC) Stock Price Crosses Above 200-Day Moving Average of $2.99

ChromaDex Co. (NASDAQ:CDXC)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.99 and traded as high as $3.47. ChromaDex shares last traded at $3.45, with a volume of 199,600 shares trading hands.

Analyst Upgrades and Downgrades

CDXC has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of ChromaDex in a report on Friday, August 9th. Roth Mkm reaffirmed a “buy” rating and issued a $6.00 price target on shares of ChromaDex in a research note on Wednesday, June 12th.

ChromaDex Price Performance

The firm has a market capitalization of $260.61 million, a price-to-earnings ratio of -69.00 and a beta of 1.87. The firm has a 50 day moving average price of $2.95 and a 200-day moving average price of $2.99.

Insider Buying and Selling at ChromaDex

In related news, Director Kristin Patrick sold 23,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 9.64% of the company’s stock.

Institutional Investors Weigh In On ChromaDex

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Miracle Mile Advisors LLC acquired a new stake in ChromaDex during the 2nd quarter worth $27,000. The Manufacturers Life Insurance Company purchased a new position in shares of ChromaDex during the second quarter worth about $31,000. Merriman Wealth Management LLC acquired a new position in ChromaDex in the 2nd quarter valued at about $32,000. Lazard Asset Management LLC purchased a new stake in ChromaDex during the 1st quarter valued at approximately $43,000. Finally, SG Americas Securities LLC acquired a new stake in ChromaDex during the 1st quarter worth approximately $54,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.